Ionis Pharmaceuticals IONS Available-for-Sale Debt Securities - Unrealized Loss Position (>=12 Months)
Available-for-Sale Debt Securities - Unrealized Loss Position (>=12 Months) at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger.
The official record: Ionis Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ionis Pharmaceuticals's available-for-sale debt securities - unrealized loss position (>=12 months).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ionis Pharmaceuticals's available-for-sale debt securities - unrealized loss position (>=12 months)?
- Ionis Pharmaceuticals (IONS) reported available-for-sale debt securities - unrealized loss position (>=12 months) of $11.32M in Q1 2026.
- How has Ionis Pharmaceuticals's available-for-sale debt securities - unrealized loss position (>=12 months) changed year-over-year?
- Ionis Pharmaceuticals's available-for-sale debt securities - unrealized loss position (>=12 months) decreased by 50.5% year-over-year, from $22.88M to $11.32M.
- What does available-for-sale debt securities - unrealized loss position (>=12 months) mean?
- The value of debt investments that have been worth less than their purchase price for over a year.
- How do you interpret available-for-sale debt securities - unrealized loss position (>=12 months)?
- An increase may signal potential credit quality concerns or a prolonged period of unfavorable market conditions for the investment portfolio.
- How does available-for-sale debt securities - unrealized loss position (>=12 months) compare across companies?
- Often low for conservative treasury management, but can rise during extended periods of market stress.